A Phase 2, Multicenter, Randomized Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder

This project is a Phase 2, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of pemvidutide in the treatment of alcohol use disorder (AUD). Building on the recognition that AUD is a chronic, relapsing condition with significant individual and public health consequences, this study seeks to determine whether pemvidutide can meaningfully reduce alcohol consumption, improve clinical outcomes, and do so with an acceptable safety profile in a diverse clinical population. The multicenter design permits assessment across varied clinical settings and populations, enhancing generalizability. Randomization and double blinding are intended to minimize bias and ensure rigorous comparison between the active treatment and placebo arms. As a Phase 2 trial, the study occupies a critical stage in clinical development: it aims to establish preliminary evidence of efficacy while continuing to collect detailed safety and tolerability data to inform potential progression to larger, definitive trials. The protocol's placebo-controlled nature allows for clear interpretation of treatment effects in the context of the expected placebo response commonly observed in addiction trials. Key components of the study include standardized enrollment criteria to identify individuals meeting diagnostic thresholds for alcohol use disorder, administration of pemvidutide or placebo according to the randomized allocation and systematic assessment of outcomes relevant to AUD.

Outcomes likely include measures of alcohol consumption frequency and quantity, periods of abstinence or relapse, and validated clinical scales assessing craving, functioning, and quality of life, alongside adverse event monitoring to capture safety signals. The multicenter approach supports recruitment efficiency and sample size targets necessary for adequate statistical power at this phase. Safety monitoring procedures and interim oversight are integral to the trial design to protect participant welfare and to ensure rapid detection and management of any emerging safety concerns. The study's findings are expected to inform dosing, safety margins, and efficacy signals that will guide subsequent Phase 3 development planning if results are favorable. Beyond regulatory considerations, results could help clinicians and patients make informed decisions about future therapeutic options for AUD. The trial also contributes to the broader scientific understanding of pharmacotherapy approaches in AUD by providing controlled clinical data on pemvidutide's performance in a rigorously designed study.

If efficacy and safety are demonstrated, pemvidutide could represent an additional option in the limited arsenal of pharmacologic treatments for AUD, addressing an important unmet medical need. Throughout, the COM emphasizes adherence to ethical standards, Good Clinical Practice, and transparent reporting to maximize the utility of the data generated for researchers, clinicians, patients, and policymakers. By focusing on robust methodology and patient-centered outcomes, this Phase 2 study aims to clarify pemvidutide's therapeutic potential and to lay the groundwork for subsequent confirmatory research.